Kura Oncology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 142
- Market Cap
- $1.5B
- Website
- http://www.kuraoncology.com
- Introduction
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.
Clinical Trials
35
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (33 trials with phase data)• Click on a phase to view related trials
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 1300
- Registration Number
- NCT07007312
A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Conditions
- Gastrointestinal Stromal Tumor (GIST)Gastrointestinal Stromal Tumor (GIST) of the Gastrointestinal TractGastrointestinal Stromal CancerGastrointestinal Stromal NeoplasmGastrointestinal Stromal Tumor, MalignantGastrointestinal Stromal Cell Tumors
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT06655246
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
- Conditions
- Solid Tumors With HRAS AlterationsNon Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)Clear Cell Renal Cell Carcinoma (ccRCC)Renal Cell Carcinoma (Kidney Cancer)
- Interventions
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06026410
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸UT Southwestern Simmons Cancer Center, Dallas, Texas, United States
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- AMLAML With Mutated NPM1Hematologic MalignancyKMT2ArNPM1 MutationMLL RearrangementLeukemiaAcute Myeloid LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute
- Interventions
- Biological: Granulocyte colony-stimulating factor
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- Kura Oncology Inc.
- Target Recruit Count
- 30
- Registration Number
- 2023-510288-37-00
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Health - Bowyer Oncology Center, Los Angeles, California, United States
Expanded Access to Ziftomenib
- Conditions
- Acute Lymphoblastic Leukemia, With Appropriate MutationsAcute Myeloid Leukemia, With NPM1 Mutations
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT05738538
- Prev
- 1
- 2
- 3
- 4
- Next
News
Kura Oncology's Ziftomenib Receives FDA Priority Review for NPM1-Mutant AML, PDUFA Date Set for November 2025
Kura Oncology's lead asset ziftomenib has advanced to FDA Priority Review for relapsed/refractory NPM1-mutant acute myeloid leukemia, with a PDUFA date of November 30, 2025.
Day One Biopharmaceuticals Appoints Michael Vasconcelles as Head of R&D to Drive Pipeline Expansion
Day One Biopharmaceuticals has appointed Michael Vasconcelles, M.D., as Head of Research and Development, bringing over 25 years of oncology research and development expertise to the company.
FDA Accepts Kura Oncology's NDA for Ziftomenib in NPM1-Mutant AML with Priority Review
The FDA has accepted Kura Oncology's new drug application for ziftomenib, an oral menin inhibitor for treating relapsed or refractory acute myeloid leukemia with NPM1 mutations.
Pharmaceutical Industry Sees Wave of Board Appointments as Companies Strengthen Leadership
Pharmaceutical and biotech companies across Europe and North America have made significant board appointments, bringing industry veterans and scientific experts to strengthen their leadership teams.
Kura Oncology Initiates Phase 1 Trial Combining Ziftomenib with Imatinib for Advanced GIST Treatment
Kura Oncology has dosed first patients in KOMET-015, a Phase 1 trial evaluating ziftomenib in combination with imatinib for advanced gastrointestinal stromal tumors (GIST) after imatinib failure.
Kura Oncology's KO-2806 Shows Promise in Combination Therapy for Renal Cell Carcinoma
Preclinical data for Kura Oncology's next-generation farnesyl transferase inhibitor KO-2806 in combination with cabozantinib has been selected for oral presentation at the 2025 AACR Annual Meeting.
Over 120 Pipeline Therapies Target Acute Myeloid Leukemia as Research Intensifies
• DelveInsight's latest report reveals a robust pipeline with 110+ companies developing 120+ therapies for acute myeloid leukemia (AML), showing significant investment in this aggressive blood cancer. • Several promising candidates are advancing through clinical trials, including GlycoMimetics' uproleselan in Phase III, BioSight's aspacytarabine (BST-236) in Phase II, and novel approaches like Senti Biosciences' logic-gated CAR-NK cell therapy. • Recent developments include Moleculin Biotech's Phase III MIRACLE trial for annamycin, Qurient's adrixetinib IND approval, and Rigel Pharmaceuticals' trial of REZLIDHIA in combination therapy for IDH1-mutated AML.
Kura Oncology and Kyowa Kirin's Ziftomenib Achieves Primary Endpoints in Phase II AML Trial
Ziftomenib, a selective oral menin inhibitor developed by Kura Oncology and Kyowa Kirin, has successfully met primary endpoints in the Phase II Komet-001 registrational trial for acute myeloid leukemia.
Kura Oncology's Menin Inhibitor Ziftomenib Shows Promise in Mid-Stage Cancer Trial
Kura Oncology and Kyowa Kirin report positive results from their Phase 2 clinical trial evaluating ziftomenib, a novel menin inhibitor for cancer treatment.
Ziftomenib Achieves Primary Endpoint in Pivotal AML Trial, Kura and Kyowa Kirin Prepare FDA Filing
Kura Oncology and Kyowa Kirin's oral menin inhibitor ziftomenib met its primary endpoint in the KOMET-001 trial for NPM1-mutated relapsed/refractory acute myeloid leukemia patients.